Program
florzolotau F-18
Also written as “[18F]-APN-1607” and “[18F]APN-1607”.
Its studies are mostly in Alzheimer Disease, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| JYAMS PET Research & Development | 22 open or running | phase 3since Jan 29, 2026 | Jan 29, 2026 | Dec 1, 2026phase 3 · NCT07422857 |
| APRINOIA Therapeutics | 10 open or running | phase 3since Jan 24, 2022 | Jan 24, 2022 | none ahead |
| APRINOIA Therapeutics | 11 open or running | phase 2since Oct 17, 2019 | Oct 17, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2019First study: phase 2 study in Alzheimer DiseaseNew to APRINOIA TherapeuticsAPRINOIA Therapeutics · NCT04141150 · 130 enrolled · United States
- Jan 24, 2022APRINOIA Therapeutics’ first study: phase 3 study in Alzheimer DiseaseNew to APRINOIA TherapeuticsAPRINOIA Therapeutics · NCT05542953 · 230 enrolled · China
- Jan 29, 2026JYAMS PET Research & Development’s first study: phase 3 study in Alzheimer DiseaseNew to JYAMS PET Research & DevelopmentJYAMS PET Research & Development · NCT07422857 · 316 planned · China
- Jul 29, 2026Phase 3 study in Alzheimer DiseaseJYAMS PET Research & Development · NCT07752784 · 12 planned · China
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Alzheimer DiseaseJYAMS PET Research & Development · NCT07422857
- Apr 30, 2027Primary completion: phase 3 study in Alzheimer DiseaseJYAMS PET Research & Development · NCT07752784
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07752784Alzheimer Disease · China | 3 | Recruiting | JYAMS PET Research & Development | Apr 30, 2027 | 12 |
| NCT07422857Alzheimer Disease · China | 3 | Recruiting | JYAMS PET Research & Development | Dec 1, 2026 | 316 |
| NCT05542953Alzheimer Disease · China | 3 | Completed | APRINOIA Therapeutics | Dec 25, 2023 | 230 |
| NCT04141150Alzheimer Disease · United States | 2 | Active, not recruiting | APRINOIA Therapeutics | Sep 2024 | 130 |
How it is read
Names in the registry
- “[18F]-APN-1607”, 2 entries
- “[18F]APN-1607”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.